Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 143-150

  Kohli, M ^a   Ferko, N ^a   Martin, A ^b   Franco, E L ^c   Jenkins, D ^d   Gallivan, S ^e   Sherlaw Johnson, C ^e   Drummond, M ^f,g  

^a Health Economics and Outcomes Research   (Canada)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d GSK   (Belgium)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f i3 Innovus   (United Kingdom)

^g UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cervical cancer; Human papillomavirus; Mathematical model; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LONG TERM CARE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PRECANCER; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS;

CALIBRATION; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MARKOV CHAINS; MASS SCREENING; MODELS, STATISTICAL; PAPILLOMAVIRUS VACCINES; PREDICTIVE VALUE OF TESTS; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 33846242622     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603501     Document Type: Article

References (46)

1. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E (1999) Psychological response to cervical screening. Prev Med 24: 610-616
2. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modeling study. Br J Cancer 91: 530-536
3. Cantor S, Atkinson E, Cardenas-Turanzas M, Benedet J, Follen M, MacAulay C (2004) Natural history of cervical intraepithelial neoplasia: a meta-analysis. 26th Annual Meeting of the Society of Medical Decision Making. Available at: http://smdm.confex.com/smdm/2004ga/techprogram/P1215.HTM
4. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005a) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490): 991-998
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005b) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164
6. Clifford GM, Smith JS, Aguado T, Franceschi S (2003a) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105
7. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S (2003b) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73
8. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6: 204
9. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J (1995) Human papillomavirus testing in primary cervical screening. Lancet 345: 1533-1536
10. De Rijke JM, van der Putten HW, Lutgens LC, Voogd AC, Kruitwagen RF, van Dijck JA, Schouten LJ (2002) Age-specific differences in treatment and survival of patients with cervical cancer in the Southeast of the Netherlands, 1986-1996. Eur J Cancer 38: 2041-2047
11. Department of Health Bulletin (2004) Cervical Screening Program, England, 2003-2004. Available at: http://www.dh.gov.UK/assetRoot/04/09/63/75/04096375. pdf
12. Ferlay J, Bray P, Pizani P, Parkin DM (2002) GLOBOCAN 2002: Cancer incidence, mortality, and prevalence worldwide. Available at: http://www-dep.iarc.fr
13. Franco EL, Cuzick J, Hildesheim A, De Sanjose S (2006) Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 (Suppl 3): S171-S177
14. Franco EL, Rohan TE, Villa LL (1999a) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91: 506-511
15. Franco EL, Villa L, Sobrinho J, Prado JM, Rousseau MC, Desy M, Rohan TE (1999b) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415-1423
16. Goldie SJ, Kohli M, Grima D, Weinstein M, Wright TC, Bosch FX, Franco E (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96: 604-615
17. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364: 1757-1765
18. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367: 1247-1255
19. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428
20. Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91: 252-258
21. Hopman EH, Kenemans P, Helmerhorst TJM (1998) Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 53: 97-106
22. IARC Handbooks of Cancer Prevention (Volume 10) (2005) Cervix Cancer Screening. International Agency for Research on Cancer, World Health Organization, 2005. Oxford University Press, Oxford, UK
23. Jenkins D, Sherlaw-Johnson C, Gallivan S (1996) Can papillomavirus testing be used to improve cervical cancer screening? Int J Cancer 65: 768-773
24. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N (2004) Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 8: 1-90
25. Kitchener HC, Wheeler P, Desai M, Corbitt G, Roberts C, Maguire P, Fletcher I, Dowie R, Moss S, Gilham C, Peto J (2004) The ARTISTIC Trial: a randomised trial in screening to improve cytology. 21st International Papillomavirus Conference, February 20-26, 2004; Mexico City, Mexico: abstract 268
26. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651
27. Kulasingham SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290: 781-789
28. Melnikov J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92: 727-735
29. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R (1998) Colposcopy for the diagnosis and management of squamous intraepithelial lesions: a meta-analysis. Review. Obstet Gynecol 91: 626-661
30. Molano M, van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S, HPV Study (2003) Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology; a Pap-based 5 year follow-up study. Am J Epidemiol 158: 486-494
31. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesions development in young females. JAMA 285: 2995-3002
32. Muñoz N, Bosch FX, Castellsagué X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285
33. National Health Services (NHS) Cervical Screening Program (2004) Colposcopy and Programme Management. Publication No 20. The Manor House, Sheffield
34. Office for National Statistics (ONS) (2002a) Registrations of Cancers Diagnosed in England. Available at: http://www.statistics.gov.UK/downloads/ theme_health/MB1_33/MB1_33.pdf
35. Office for National Statistics (ONS) (2002b) Mortality Statistics. Available at: http://www.statistics.gov.uk/downloads/theme_health/Dh2_29/ DH2No29. pdf
36. Office for National Statistics (ONS) (2003) Mid-2001 Population Estimates for Females in United Kingdom. Available at: http://www. statistics.gov.uk/popest
37. Parkin DM (1966) Cancer incidence in five continents. International Agency for Research on Cancer; Table 21 B: England and Wales; Volume 1
38. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M (2004b) Cervical HPV infection and neoplasia in a large population based prospective study: The Manchester Cohort. Br J Cancer 91: 942-953
39. Peto J, Gilham C, Fletcher O, Matthews FE (2004a) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364: 249-256
40. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95: 1336-1343
41. Sherlaw-Johnson C, Gallivan S, Jenkins D (1999) Withdrawing low risk women from cervical screening programmes: mathematical modeling study. BMJ 318: 356-361
42. Sherlaw-Johnson C, Gallivan S, Jenkins DH, Jones MH (1994) Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modeling. J Clin Pathol 47: 430-435
43. Sherlaw-Johnson S, Philips Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 91: 84-91
44. Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10: 1915-1923
45. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson S, Steinwall M, Brown DR, Kurman RJ, Ronnett BR, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar F, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278
46. Wallace LA, Bramley JC, Ahmed S, Duff R, Hutchinson SJ, Carman WF, Kitchin NR, Goldberg DJ (2004) Determinants of universal adolescent hepatitis B vaccination uptake. Arch Dis Child 89: 1041-1042